141 related articles for article (PubMed ID: 33765933)
21. Access to essential medicines to treat chronic respiratory disease in low-income countries.
Bissell K; Perrin C; Beran D
Int J Tuberc Lung Dis; 2016 Jun; 20(6):717-28. PubMed ID: 27155173
[TBL] [Abstract][Full Text] [Related]
22. Impact of pharmaceutical price controls on the cost of cardiovascular drugs: does essentiality matter?
Khanijo S; Kakkar AK; Kumar R; Patil AN; Bhusal G; Vishwas G; Arora G
Expert Rev Clin Pharmacol; 2020 Jul; 13(7):797-806. PubMed ID: 32552127
[TBL] [Abstract][Full Text] [Related]
23. Beneficiaries with cardiovascular disease and thePart D coverage gap.
Polinski JM; Shrank WH; Glynn RJ; Huskamp HA; Roebuck MC; Schneeweiss S
Circ Cardiovasc Qual Outcomes; 2012 May; 5(3):387-95. PubMed ID: 22511746
[TBL] [Abstract][Full Text] [Related]
24. Essential diabetes medicines and health outcomes in 127 countries.
Budhram D; Benipal S; Bilimoria K; Maraj D; Wang R; Persaud N
Diabetes Obes Metab; 2021 May; 23(5):1121-1128. PubMed ID: 33417268
[TBL] [Abstract][Full Text] [Related]
25. Access to Antihypertensive Drugs in China.
Bai G; Bennet C; Wang J; Anderson GF
Circulation; 2018 Oct; 138(17):1777-1779. PubMed ID: 30354658
[No Abstract] [Full Text] [Related]
26. Availability and affordability of essential medicines for children in the Western part of Ethiopia: implication for access.
Sado E; Sufa A
BMC Pediatr; 2016 Mar; 16():40. PubMed ID: 26979737
[TBL] [Abstract][Full Text] [Related]
27. Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data.
Khatib R; McKee M; Shannon H; Chow C; Rangarajan S; Teo K; Wei L; Mony P; Mohan V; Gupta R; Kumar R; Vijayakumar K; Lear SA; Diaz R; Avezum A; Lopez-Jaramillo P; Lanas F; Yusoff K; Ismail N; Kazmi K; Rahman O; Rosengren A; Monsef N; Kelishadi R; Kruger A; Puoane T; Szuba A; Chifamba J; Temizhan A; Dagenais G; Gafni A; Yusuf S;
Lancet; 2016 Jan; 387(10013):61-9. PubMed ID: 26498706
[TBL] [Abstract][Full Text] [Related]
28. Access to medicines versus access to treatment: the case of type 1 diabetes.
Beran D; McCabe A; Yudkin JS
Bull World Health Organ; 2008 Aug; 86(8):648-9. PubMed ID: 18797626
[No Abstract] [Full Text] [Related]
29. Pain Treatment Continues To Be Inaccessible for Many Patients Around the Globe: Second Phase of Opioid Price Watch, a Cross-Sectional Study To Monitor the Prices of Opioids.
Pastrana T; Wenk R; Radbruch L; Ahmed E; De Lima L
J Palliat Med; 2017 Apr; 20(4):378-387. PubMed ID: 27923102
[TBL] [Abstract][Full Text] [Related]
30. The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries.
Mendis S; Fukino K; Cameron A; Laing R; Filipe A; Khatib O; Leowski J; Ewen M
Bull World Health Organ; 2007 Apr; 85(4):279-88. PubMed ID: 17546309
[TBL] [Abstract][Full Text] [Related]
31. A survey of availability, price and affordability of essential medicines from 2011 to 2016 in Chinese secondary and tertiary hospitals.
Guan X; Hu H; Man C; Shi L
Int J Equity Health; 2018 Oct; 17(1):158. PubMed ID: 30340587
[TBL] [Abstract][Full Text] [Related]
32. Essential cancer medicines and cancer outcomes: Cross-sectional study of 124 countries.
Ikpeni OT; Maraj D; Woods H; Workentin A; Booth CM; Persaud N
Cancer Med; 2023 Nov; 12(22):20745-20758. PubMed ID: 37902259
[TBL] [Abstract][Full Text] [Related]
33. Access to affordable medicines after health reform: evidence from two cross-sectional surveys in Shaanxi Province, western China.
Fang Y; Wagner AK; Yang S; Jiang M; Zhang F; Ross-Degnan D
Lancet Glob Health; 2013 Oct; 1(4):e227-37. PubMed ID: 25104348
[TBL] [Abstract][Full Text] [Related]
34. Ensuring access to essential medicines: some economic considerations.
Maskus KE
Spec Law Dig Health Care Law; 2003 Jul; (291):9-25. PubMed ID: 15206162
[No Abstract] [Full Text] [Related]
35. WHO essential medicines policies and use in developing and transitional countries: an analysis of reported policy implementation and medicines use surveys.
Holloway KA; Henry D
PLoS Med; 2014 Sep; 11(9):e1001724. PubMed ID: 25226527
[TBL] [Abstract][Full Text] [Related]
36. The cost effectiveness of cardiovascular medicines.
Hay J
Curr Atheroscler Rep; 2005 Mar; 7(2):79-80. PubMed ID: 15727719
[No Abstract] [Full Text] [Related]
37. Developing nations and the compulsory license: maximizing access to essential medicines while minimizing investment side effects.
Bird RC
J Law Med Ethics; 2009; 37(2):209-21. PubMed ID: 19493067
[TBL] [Abstract][Full Text] [Related]
38. Availability, Price, and Affordability of Essential Medicines to Manage Noncommunicable Diseases: A National Survey From Nepal.
Khanal S; Veerman L; Ewen M; Nissen L; Hollingworth S
Inquiry; 2019; 56():46958019887572. PubMed ID: 31823665
[TBL] [Abstract][Full Text] [Related]
39. Access to diagnostic tests and essential medicines for cardiovascular diseases and diabetes care: cost, availability and affordability in the West Region of Cameroon.
Jingi AM; Noubiap JJ; Ewane Onana A; Nansseu JR; Wang B; Kingue S; Kengne AP
PLoS One; 2014; 9(11):e111812. PubMed ID: 25369455
[TBL] [Abstract][Full Text] [Related]
40. Availability, prices and affordability of essential medicines for children: a cross-sectional survey in Jiangsu Province, China.
Sun X; Wei J; Yao Y; Chen Q; You D; Xu X; Dai J; Yao Y; Sheng J; Li X
BMJ Open; 2018 Oct; 8(10):e023646. PubMed ID: 30341137
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
